- PROVIDERS
-
LIFE SCIENCES
UPCOMING WEBINAR
Increasing Probability of Technical Success Using Multimodal Data
Learn how AstraZeneca is using multimodal RWD data to aid in the design of all Phase 3 studies -
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
- ABOUT US
Data-driven
precision medicine
Bringing the power of data and artificial intelligence to healthcare
With the power of AI, we now have the ability to
-
ACCELERATE
the discovery of novel targets
-
PREDICT
the effectiveness of treatments
-
IDENTIFY
potentially life-saving clinical trials
-
DIAGNOSE
multiple diseases earlier
Explore Tempus
LIFE SCIENCES
We can assist pharmaceutical and biotech companies with better drug development.
Learn More
OUR PLATFORM
We have built a proprietary Platform to make data accessible and deploy AI at scale.
Learn MoreOur Science
Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Improving patient care through high quality testing, clinical trial matching, and deep research data that powers scientific discovery
50%+ of all Academic Medical Centers in the US are connected to Tempus
40%+ of oncologists in the US connected to Tempus through sequencing, clinical trial matching, and research-enabled partnerships
90% of the top 20 pharma oncology companies partner with Tempus
160+ biopharma partnerships
6,000,000+ de-identified research records to power scientific discovery to improve patient outcomes
20,000+ patients were identified for potential enrollment into clinical trials in our network
70+ petabytes of data
GSK Announces Expanded Collaboration with Tempus in Precision Medicine to Accelerate R&D
The expanded collaboration bolsters GSK’s data science and AI-driven R&D efforts, providing the company access to Tempus’ AI-enabled platform to support improved clinical trial design, speed up enrollment, and identify drug targets.
READ PRESS RELEASETempus Announces Dr. Kate Sasser as Chief Scientific Officer
Kate Sasser, PhD, joined Tempus as its Chief Scientific Officer. Dr. Sasser is applying her extensive experience in translational research, precision medicine, data science, and drug discovery to bring personalized medicine solutions to Tempus’ life science collaborators, physicians, and patients.
READ PRESS RELEASETempus Launches First Cardiology Prospective Study for its AI-Enabled Predictive Tests
Tempus launches its multi-center study titled, “Electrocardiogram-based Artificial Intelligence-Assisted Detection of Heart Disease,” or ECG-AID, which aims to evaluate the impact of the company’s investigational, AI-enabled, predictive tests in cardiology and focuses on finding patients at high risk of developing atrial fibrillation (AFib) or any of seven structural heart diseases (SHD).
READ PRESS RELEASEThis is data-driven precision medicine
This is the future of healthcare.